UQUIFA

Belkins
Uquifa is the API division of Vivimed Labs. Uquifa is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical Industry. Operates 3 manufacturing sites, 2 in Spain and 1 in Mexico, which operates under cGMP conditions and has been inspected and approved by major Pharmaceutical Companies and Regulatory Authorities, including the US FDA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

news image

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More

CELL AND GENE THERAPY

PACBIO ACQUIRES OMNIOME, A DNA SEQUENCING STARTUP, FOR UP TO $800 MILLION

PacBio | July 26, 2021

news image

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacB...

Read More

INDUSTRIAL IMPACT

PALANTIR AND DEWPOINT THERAPEUTICS ANNOUNCE STRATEGIC PARTNERSHIP

Palantir Technologies Inc. | December 21, 2021

news image

Palantir Technologies Inc. a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics the leading biomolecular condensates company, announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases. Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with oth...

Read More

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

news image

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More
news image

MEDTECH

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More
news image

CELL AND GENE THERAPY

PACBIO ACQUIRES OMNIOME, A DNA SEQUENCING STARTUP, FOR UP TO $800 MILLION

PacBio | July 26, 2021

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacB...

Read More
news image

INDUSTRIAL IMPACT

PALANTIR AND DEWPOINT THERAPEUTICS ANNOUNCE STRATEGIC PARTNERSHIP

Palantir Technologies Inc. | December 21, 2021

Palantir Technologies Inc. a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics the leading biomolecular condensates company, announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases. Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with oth...

Read More
news image

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More